Regeneron Pharmaceuticals is facing significant selling pressure as investors react to recent developments in its partnership with Sanofi.
Shares of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) fell sharply, closing down 6.71% to CA$725.92. This decline comes during a week when the broader healthcare sector has struggled, with the S&P 500 Health Care Sector Index slipping 2.66%. Investors are concerned about Regeneron’s recent expansion of its immunology alliance with Sanofi, which has led to today’s sell-off.
Investor takeaway: Investors should be cautious as Regeneron’s recent partnership terms may dilute future profit margins, raising questions about the sustainability of its growth.
Advertisement
Regeneron Pharmaceuticals Inc
REGN.US
REGN.US
Regeneron Pharmaceuticals Inc
WealthAwesomeMarket cap
$78.07B
P/E
18.6x
Div. yield
0.49%
Div. / share
$3.64
52W high
$859.34
52W low
$538.24
1W change
-7.69%
Beta
0.19
Analyst Price Targets
Based on 25 analysts covering REGN · as of Sep 25, 2026
Wall Street analysts forecast REGN stock price to rise 15.8% over the next 12 months.
Consensus
Buy4.28 / 5.00
Avg. Target
C$850.88
+15.8% Upside
Previously C$849.32 on Sep 17, 2026
Current Price
C$734.81
Last close
Analyst Breakdown (25 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on REGN's historical volatility
30-Day Vol
28.4%
Annualized
90-Day Vol
30.3%
Annualized
Trend (90d)
+43.8%
Annualized drift
90d Mean
C$859.10
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$774.10 | C$701.74 – C$853.93 |
| 60 trading days | C$815.50 | C$709.81 – C$936.92 |
| 90 trading days | C$859.10 | C$724.80 – C$1018.29 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Bull case
Regeneron has a strong pipeline of drugs and a history of successful collaborations. This could lead to significant revenue from new therapies in the long run.
Bear case
The recent deal with Sanofi may limit Regeneron's profit potential from its blockbuster drug Dupixent. The market's reaction suggests that investor confidence is wavering.
Market Reaction to Partnership Terms
Regeneron’s stock price fell sharply after the announcement of its expanded partnership with Sanofi, which included a $1 billion upfront payment and potential for up to $7 billion in milestone payments. However, investors were disappointed that the existing profit-sharing terms for Dupixent remained unchanged, leading to concerns about the dilution of future profits from this key product.
Advertisement
Broader Healthcare Sector Weakness
The decline in Regeneron’s stock is part of a larger trend affecting the healthcare sector, with the S&P 500 Health Care Sector Index down 2.66% for the week. This broader weakness may be contributing to the negative sentiment surrounding Regeneron, as investors reassess the valuation of healthcare stocks amid rising costs and regulatory pressures.
Future Outlook for Regeneron
Despite the current downturn, Regeneron holds a diverse pipeline of drugs and a strong history of innovation. However, the market's reaction indicates that investors are wary of the potential impact of the recent partnership on long-term profitability. As the company navigates these challenges, its ability to deliver on new therapies will be crucial for regaining investor confidence.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
